) has been revised to $15.81 / share. This is an increase of 25.68% from the prior estimate of $12.58 dated November 14, 2025. The price target is an average of many targets provided by analysts. The ...
Hosted on MSN
Cantor Fitzgerald Initiates Coverage of DiaMedica Therapeutics (DMAC) with Overweight Recommendation
Fintel reports that on November 14, 2025, Cantor Fitzgerald initiated coverage of DiaMedica Therapeutics (NasdaqCM:DMAC) with a Overweight recommendation. Analyst Price Forecast Suggests 112.14% ...
The average one-year price target for DiaMedica Therapeutics (NasdaqCM:DMAC) has been revised to $15.81 / share. This is an increase of 25.68% from the prior estimate of $12.58 dated November 14, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results